You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Geron said quarterly net revenue topped $60 million and plans a commercial sale in Germany before the end of the year. Rytelo reached 1,700 accounts, while first- or second-line patients represented 36% of its patient population.
Geron reported third-quarter net revenue of $60.1 million, maintained 2026 net revenue guidance of $220 million to $240 million, began a gated European launch beginning with Germany, and lowered operating expense guidance to $220 million to $230 million.
Geron Corporation reported third-quarter 2026 RYTELO net product revenue of $60.1 million and net income of $1.4 million, versus a net loss of $18.4 million a year earlier. It initiated a gated RYTELO launch in targeted European markets.
Geron Corporation discontinued the Phase 3 IMpactMF trial of imetelstat after the independent DMC said it was unlikely to meet the overall survival endpoint; no new safety signals required additional monitoring.
Useful current figures from the complete screener profile.
TL;DR. Geron reported Q2 2026 RYTELO net revenue of $57.5M (+17% YoY, +11% QoQ) with 5% demand growth and ~8% more ordering accounts (~1,575), and now expects to land at the mid-to-high end of its $220–240M full-year RYTELO revenue guidance. The company is evaluating a modification to the interim event threshold for the Phase 3 IMpactMF trial, with projected timelines unchanged; first-half operating expenses fell 4% as net revenue rose 24%, and cash stood at ~$327M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GERN
this stock
Geron Corp
|
$622.98M | -26.7% | -82.7% | — | 10.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Geron said quarterly net revenue topped $60 million and plans a commercial sale in Germany before the end of the year. Rytelo reached 1,700 accounts, while first- or second-line patients represented 36% of its patient population.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GERN | -2.3% | -17.4% | -24.5% | +8.1% | -26.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.9% | -16.2% | -25.0% | +8.3% | -37.4% |
